The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab) in seven European countries. Breast cancer blockbuster Herceptin earned $2.26 billion in ...

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like ...

Clarity Pharmaceuticals has added 64/67Cu-SAR-trastuzumab to its Targeted Copper Theranostic (TCT) portfolio, strengthening ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Human uptake of microplastic particles (MPs) is causing increasing health concerns, and there is mounting pressure to evaluate the associated risks. While MPs can be ingested, breathed in, or drank in ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).